公开(公告)号：US5135874A

公开(公告)日：1992-08-04

申请号：US493659

申请日：1990-03-15

申请人： Pamela C. Esmon ,  Michael A. Fournel

发明人： Pamela C. Esmon ,  Michael A. Fournel

IPC分类号： G01N33/86

CPC分类号： G01N33/86 ,  G01N2333/755 ,  G01N2333/81 ,  Y10S436/815 ,  Y10S436/821 ,  Y10S436/824

摘要： A method for evaluating the potential immunogenicity of a protein derived from recombinant DNA technology. The method involves injecting an animal with the recombinant protein and then isolating antiserum from the animal. The antiserum is depleted of antibodies to a reference protein, i.e., a plasma derived protein, by adsorbing the antiserum against the reference protein. The adsorbed antiserum is then blotted against the recombinant protein, to see if any antibodies were produced which recognize the recombinant protein, but did not recognize the plasma-derived protein during adsorption.

摘要翻译： 一种用于评估衍生自重组DNA技术的蛋白质的潜在免疫原性的方法。 该方法包括向动物注射重组蛋白，然后从动物中分离抗血清。 抗血清通过将抗血清吸附在参照蛋白上而消耗参考蛋白的抗体，即血浆衍生的蛋白质。 然后将吸附的抗血清与重组蛋白质印迹，以观察是否产生识别重组蛋白但在吸附期间不识别血浆衍生蛋白质的抗体。

公开(公告)号：US4391801A

公开(公告)日：1983-07-05

申请号：US316201

申请日：1981-10-29

申请人： Paul K. Ng ,  Michael A. Fournel

发明人： Paul K. Ng ,  Michael A. Fournel

IPC分类号： A61K35/14 ,  A61K35/16 ,  A61K38/16 ,  A61P7/00 ,  A61K37/02 ,  A61K37/04

CPC分类号： A61K35/16 ,  Y10S530/83 ,  Y10S530/831

摘要： Stable plasma protein fractions (PPF) substantially free of vasodepressant amounts of acetate ions are disclosed. Solutions of the disclosed PPF are suitable for intravenous administration to patients without deleterious vasodepressor effects. Methods are also described for preparing the aforementioned PPF.

摘要翻译： 公开了基本上不含血管抑制剂量的乙酸根离子的稳定的血浆蛋白质级分（PPF）。 所公开的PPF的解决方案适用于静脉内给予无有害的血管抑郁症作用的患者。 还描述了制备上述PPF的方法。

公开(公告)号：US5147779A

公开(公告)日：1992-09-15

申请号：US202177

申请日：1988-06-01

申请人： Pamela C. Esmon ,  Michael A. Fournel

发明人： Pamela C. Esmon ,  Michael A. Fournel

IPC分类号： G01N33/86

CPC分类号： G01N33/86 ,  G01N2333/755 ,  G01N2333/81 ,  Y10S436/824

摘要： A method for evaluating the potential immunogenicity of a protein derived from recombinant DNA technology. The method involves injecting an animal with the recombinant protein and then isolating antiserum from the animal. The antiserum is depleted of antibodies to a reference protein, i.e., a plasma derived protein, by adsorbing the antiserum against the reference protein. The adsorbed antiserum is then blotted against the recombinant protein, to see if any antibodies were produced which recognize the recombinant protein, but did not recognize the plasma-derived protein during adsorption.